HC Wainwright Issues Positive Forecast for FULC Earnings

Key Points

• HC Wainwright has raised its Q3 2025 EPS estimate for Fulcrum Therapeutics to ($0.26), indicating a positive outlook, with a "Buy" rating and a price target of $12.00.
• Fulcrum Therapeutics recently reported earnings of ($0.28) per share, surpassing the consensus estimate of ($0.29) by $0.01.
• Institutional ownership in Fulcrum Therapeutics is significant, with 89.83% of the stock held by institutional investors, highlighting strong confidence in the company's potential.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Tuesday, July 29th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.26) per share for the quarter, up from their prior estimate of ($0.28). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics' Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at ($0.96) EPS and FY2029 earnings at ($0.65) EPS.

Several other brokerages have also recently issued reports on FULC. Royal Bank Of Canada raised their target price on Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a "sector perform" rating in a research report on Wednesday, July 30th. Piper Sandler reissued an "overweight" rating and issued a $9.00 price target (up from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Leerink Partnrs raised Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. Leerink Partners raised Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $4.00 to $12.00 in a report on Friday, May 23rd. Finally, Cantor Fitzgerald upgraded Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a research note on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Fulcrum Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $7.57.

Fulcrum Therapeutics Price Performance

NASDAQ FULC traded down $0.12 during trading hours on Friday, hitting $6.85. The company's stock had a trading volume of 287,607 shares, compared to its average volume of 591,881. Fulcrum Therapeutics has a 12 month low of $2.32 and a 12 month high of $10.13. The company's 50 day simple moving average is $7.18 and its two-hundred day simple moving average is $5.02. The company has a market cap of $370.25 million, a P/E ratio of -5.63 and a beta of 2.47.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01.

Institutional Trading of Fulcrum Therapeutics

Institutional investors have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC increased its position in shares of Fulcrum Therapeutics by 26.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company's stock worth $89,000 after purchasing an additional 2,677 shares in the last quarter. Aberdeen Group plc purchased a new position in shares of Fulcrum Therapeutics during the 2nd quarter worth $404,000. Strs Ohio purchased a new position in shares of Fulcrum Therapeutics during the 1st quarter worth $263,000. Acadian Asset Management LLC increased its holdings in shares of Fulcrum Therapeutics by 865.0% during the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company's stock worth $989,000 after buying an additional 308,854 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in Fulcrum Therapeutics by 62.1% in the 1st quarter. Jane Street Group LLC now owns 117,816 shares of the company's stock valued at $339,000 after purchasing an additional 45,157 shares in the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.